AIM ImmunoTech (AIM) vs Senti Biosciences (SNTI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Senti Biosciences is the larger company by market cap ($10.0 million vs $7.2 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AIM | SNTI |
|---|---|---|
| Share price | $0.1796 | $0.3217 |
| Market cap | $7.17M | $10.02M |
| 1-day change | -1.75% | -2.52% |
| YTD return | — | -69.07% |
| 1-year return | — | -81.93% |
| 5-year return | — | -99.68% |
| EPS (TTM) | $-2.98 | $-1.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.79 | $2.88 |
| 52-week low | $0.17 | $0.29 |
| Distance from 52-week high | -93.57% | -88.83% |
| Analyst consensus | none | none |
| Avg. price target upside | +2266.37% | +4096.46% |
| Average volume | 4.70M | 573.78K |
| Shares outstanding | 39.89M | 31.15M |
| Employees | 19 | 39 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AIM ImmunoTech
AIM stock →AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 19 employees
About Senti Biosciences
SNTI stock →Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees
AIM vs SNTI FAQ
Which is bigger, AIM ImmunoTech or Senti Biosciences?
Senti Biosciences (SNTI) is larger, with a market capitalization of $10.02M compared with $7.17M for AIM ImmunoTech (AIM).
Are AIM ImmunoTech and Senti Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.